The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Biomarker analyses and association with clinical outcomes in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib with or without erlotinib in the phase III SEARCH trial.
Andrew X. Zhu
Consultant or Advisory Role - Daiichi Sankyo; Eisai; Exelixis; Sanofi
Research Funding - Bayer; Lilly
Yoon-Koo Kang
Consultant or Advisory Role - Bayer
Research Funding - Bayer
Olivier Rosmorduc
Honoraria - Bayer; Roche
T.R. Jeffry Evans
Honoraria - Bayer
Research Funding - Bayer
Other Remuneration - Bayer
Armando Santoro
Consultant or Advisory Role - Amgen; Bayer; GlaxoSmithKline; Roche; Takeda
Honoraria - ArQule
Paul J. Ross
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Other Remuneration - Celgene
Edward Gane
No relevant relationships to disclose
Arndt Vogel
Honoraria - Amgen; Bayer; Celgene; Roche
Research Funding - Amgen
Michael Jeffers
Employment or Leadership Position - Bayer
Gerold Meinhardt
Employment or Leadership Position - Bayer
Carol Elaine Pena
Employment or Leadership Position - Bayer